NCT02278562View on ClinicalTrials.gov

Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

October 22, 2014

Primary Completion Date

March 1, 2017

Study Completion Date

March 1, 2017

Conditions
ESRD
Interventions
DRUG

anakinra

100 mg in syringes; administered subcutaneously 3 times a week for 12 weeks (3 months)

DRUG

actos

30 mg capsules; administered orally 1 capsule per day for 12 weeks (3 months)

OTHER

placebo

placebo capsules and injection

Trial Locations (1)

37212-2637

Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville

All Listed Sponsors
lead

VA Office of Research and Development

FED

NCT02278562 - Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2 | Biotech Hunter | Biotech Hunter